FDA grants 12-year exclusivity to Flublok; Emergent BioSolutions' Ebola candidate enters Ph I;

> The FDA granted 12-year exclusivity to Protein Sciences' Flublok, which means no product similar to Flublok can be approved by the FDA before Jan. 16, 2025. Release

> Emergent BioSolutions' ($EBS) investigational Ebola vaccine, produced using ProBioGen's platform, has entered clinical trials at Oxford University in the U.K. Release

> Griffith University's Institute for Glycomics has developed a combination vaccine that may beat Streptococcus A infections. Human trials may begin as early as 2016. More

> Soligenix announced data demonstrating a heat-stable formulation of an HPV vaccine. Release

Suggested Articles

Pfizer and BioNTech followed supply pacts in the U.S. and U.K. with a new deal to deliver 120 million vaccines to Japan in the first half of 2021.

Sanofi's cost cuts are adding up, execs said in an update Wednesday. The company has trimmed nearly €1 billion in annual expenses so far in 2020.

Shingrix sales in the second quarter plummeted by half from first-quarter levels, and recovery of vaccination rates remains slow amid the pandemic.